肝癌qBiomarker体细胞突变PCR芯片Liver Ca

“英拜为您实验加速”
技术服务网址：http://www.yingbio.com/
服务热线：400-696-6643、 18019265738
邮箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

Liver Cancer qBiomarker Mutation PCR Array

肝癌qBiomarker体细胞突变PCR芯片

Product	Species	Technology	Cat. No.
Liver Cancer qBiomarker Mutation PCR Array	Human	Somatic Mutation	SMH-034A

The Human Liver Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the somatic mutations in human liver cancer samples in the following key genes: BRAF, CTNNB1, ERBB2, FBXW7, HNF1A, KRAS, NRAS, PIK3CA, and P53.


These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Liver Cancer qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of liver cancer and has the potential for discovery and development of effective biomarkers for this cancer type and other cancer types in which these mutations were identified. This array includes 85 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human liver cancer. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent the most frequently recurring somatic mutations compiled from over 2700 liver cancer samples. The simplicity of the product format and operating procedure enables routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments.
肝癌qBiomarker体细胞突变PCR芯片是一个翻译研究工具,用于快速,准确,全面剖析人类肝癌样本中体细胞突变的关键基因：BRAF, CTNNB1, ERBB2, FBXW7, HNF1A, KRAS, NRAS, PIK3CA, and P53。这些突变保证广泛的研究,以提高致癌作用的理解和鉴定潜在的药物靶点。已有许多研究通过单个和多个体细胞突变状态信息鉴定关键信号转导中断。例如,EGFR和KRAS基因的突变状态可以预测某些药物针对这些分子的生理反应。人类肝癌qBiomarker体细胞突变PCR芯片以其全面的内容覆盖范围，用于研究肝癌的环境突变且有潜力用于发现靶向药物的生物标记并验证这些癌症和其他这些突变已确定的癌症。这个芯片包含85个DNA突变序列用于检测最频繁的，功能性验证，在人类肝癌显著突变。这些突变的选择根据全面的体细胞突变数据库和重要文献，来自2700多个CNS肝癌样本发生最频繁重复编译的体细胞突变。简单的产品模式和操作程序让任何一个具备实时定量PCR仪的实验室都可进行常规的体细胞突变分析。

BRAF: 2 Assays
There are two major classes of BRAF mutations. One class leads to increased BRAF kinase activity, such as the p. V600E mutation. The other class leads to impaired kinase activity, such as the p.G469A mutation.
CTNNB1: 29 Assays
The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
ERBB2: 1 Assay
The most frequently identified ERBB2 activating mutations cluster in the ERBB2 kinase domain region.
FBXW7: 1 Assay
Typically detected mutations lay in either the third or fourth repeat of the protein's WD40 domain, typically involved in protein-protein interactions.
HNF1A: 2 Assays
These mutations are expected to interfere with DNA binding.
KRAS: 12 Assays
The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
NRAS: 2 Assays
The most important NRAS mutations in liver cancer occur at codon 61.
PIK3CA: 2 Assays
The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
TP53: 34 Assays
The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure.